help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on December 20, 2007, doi:10.1165/rcmb.2007-0279RC

Am. J. Respir. Cell Mol. Biol., Volume 38, Number 3, March 2008, 256-262

A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2007-0279RCv1
38/3/256    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, L. P
Right arrow Articles by Bond, R. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, L. P
Right arrow Articles by Bond, R. A

Submitted on July 23, 2007
Revised on December 17, 2007

Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model

Long P Nguyen1, Ozozoma Omoluabi2, Sergio Parra1, Joanna M Frieske1, Cecilia Clement3, Zoulikha Ammar-Aouchiche3, Samuel B Ho4, Camille Ehre5, Mehmet Kesimer5, Brian J Knoll1, Michael J Tuvim3, Burton F Dickey3, and Richard A Bond1*

1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX, USA, 2 Department of Biology and Biochemistry, University of Houston, Houston, TX, USA, 3 Department of Pulmonary Medicine, M.D. Anderson Cancer Center, Houston, TX, USA; Texas A and M University System Houston Health Science Center, Institute of Biosciences and Technology, Houston, TX, USA, 4 Department of Medicine, Veterans Affairs San Diego Healthcare System and University of California, San Diego, CA, USA, 5 Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC, USA

* To whom correspondence should be addressed. E-mail: RABond{at}uh.edu.

Single dose administration of beta-adrenoceptor agonists produces bronchodilation and inhibits AHR, and is the standard treatment for the acute relief of asthma. However, chronic repetitive administration of beta-adrenoceptor agonists may increase AHR, airway inflammation, and risk of death. Based upon the paradigm shift that occurred with the use of beta-blockers in congestive heart failure, we previously determined that chronic administration of beta-blockers decreased AHR in a murine model of asthma. To elucidate the mechanisms for the beneficial effects of beta-blockers, we examined the effects of chronic administration of several beta-adrenoceptor ligands in a murine model of allergic asthma. Administration of beta-blockers resulted in a reduction in total cell counts, eosinophils, and the cytokines IL-13, IL-10, IL-5, and TGF-{beta}1 in bronchoalveolar lavage, and attenuated epithelial mucin content and morphologic changes. The differences in mucin content also occurred if the beta-blockers were administered only during the ovalbumin challenge phase, but administration of beta-blockers for 7 days was not as effective as 28 days. These results indicate that in a murine model of asthma, chronic administration of beta-blockers reduces inflammation and mucous metaplasia, cardinal features of asthma that may contribute to airflow obstruction and AHR. Similar to heart failure, our results provide a second disease model where beta-blockers producing an acutely detrimental effect may provide a therapeutically beneficial effect with chronic administration.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2007 American Thoracic Society.